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Abstract
Autoimmune thyroid disease (AITD) is often observed together with other
autoimmune diseases. The coexistence of two or more autoimmune diseases
in the same patient is referred to as polyautoimmunity, and AITD is the
autoimmune disease most frequently involved. The occurrence of
polyautoimmunity has led to the hypothesis that the affected patients suffer
from a generalized dysregulation of their immune system. The present review
summarizes recent discoveries unravelling the immunological mechanisms
involved in autoimmunity, ranging from natural autoimmunity to disease-specific
autoimmunity. Furthermore, the clinical grounds for considering AITD in a
setting of polyautoimmunity are explored. A better understanding of these may
pave the way for designing new treatment modalities targeting the underlying
immune dysregulation when AITD appears in the context of polyautoimmunity.
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Introduction
Autoimmune thyroid diseases (AITDs), comprising the two 
main entities Hashimoto’s thyroiditis (HT) and Graves’ disease 
(GD), are the most common autoimmune diseases1 and are often 
observed together with other autoimmune diseases. The occurrence 
of two or more diseases in the same patient is often referred to 
as polyautoimmunity2. This has led to the hypothesis that many 
patients with autoimmune disease, in general, suffer from an 
underlying dysfunction of critical mechanisms ensuring self- 
tolerance. The present review examines recent advances in the 
understanding of immunological aspects involved in autoimmu-
nity, ranging from physiological to disease-specific autoimmunity, 
and explores the clinical grounds for considering thyroid 
autoimmunity in a setting of polyautoimmunity.
Immunological aspects of polyautoimmunity
Natural polyautoimmunity
At the beginning of the 20th century, Paul Ehrlich demonstrated 
that animals do not produce antibodies against their own red blood 
cells and coined the term “horror autotoxicus” for the immune 
system’s reaction with the body’s own constituents3,4. At the same 
time, the normal occurrence of autoantibodies against spermatozoa 
was demonstrated5. Since then, many studies have shown the exist-
ence of autoantibodies in healthy animals and humans, referred to 
as natural autoantibodies6,7. In general, natural autoantibodies show 
broad reactivity against more self- and non-self-antigens and are 
of the IgM isotype6,8, whereas disease-associated autoantibodies 
are of the IgG isotype and bind specific self-antigens with high 
affinity9,10. At least in mice, the subset of B cells producing natural 
autoantibodies appears to be positively selected for self-reactivity in 
the bone marrow11. Although B cells and T cells binding to “self” with 
high affinity are negatively selected, self-reactive lymphocytes with 
low-affinity receptors are allowed to escape and enter the circulation 
but often without harmful consequences12,13. Thus, natural autoan-
tibodies may serve a role in the clearance of aging cells and cells 
with tumor potential and may also exert anti-inflammatory control 
over B cells and T cells14,15. Natural autoimmunity should therefore 
should be distinguished from disease-associated autoimmunity.
Loss of self-tolerance
Autoimmune disease is preceded by loss of immunological self-
tolerance, which may occur at the central level (during the selec-
tion processes described above) or in the periphery. The adaptive 
immune system’s T cells and B cells usually keep the balance 
between reacting aptly toward foreign antigens and avoiding 
attack on “self”. Both T cells and B cells contain subsets of reg-
ulatory cells with an immunoregulatory cytokine profile on the 
one hand and effector cells that produce antibodies or secrete pro-
inflammatory cytokines on the other (Figure 1). Thus, the tradi-
tional view of a T helper type 1 (Th1)/Th2 dichotomy has been 
abandoned since it became clear that CD4+ effector T cells can dif-
ferentiate into several subsets of Th cells which stimulate differ-
ent parts of the immune system: for example, Th1 cells stimulate 
cellular immunity and the production of opsonizing antibodies, 
Th2 cells stimulate IgE production, and Th17 cells stimulate neu-
trophils. Th1 cells and Th17 cells have been shown to play detrimen-
tal roles in many autoimmune diseases, including HT and GD16,17. 
Furthermore, Th17 cells have been associated with chronic 
Figure 1. B-cell and T-cell subsets controlling autoimmunity. Peripheral self-tolerance is ensured by regulatory B cells and T cells. 
Autoimmunity (loss of self-tolerance) is considered to be due to a shift in favor of pro-inflammatory effector cells. Beff, effector B cells; Breg, 
regulatory B cells; DC, dendritic cell; IL, interleukin; iTreg, induced regulatory T cells; TGF-β, transforming growth factor beta; Th1,2,17, effector 
CD4+ T-cell subsets with different cytokine profiles.
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inflammation and autoimmune diseases such as systemic lupus 
erythematosus, Sjögren’s syndrome, and systemic sclerosis18.
Regulatory T cells (Tregs) are primarily responsible for maintaining 
self-tolerance, and a protective role of Tregs has been demonstrated 
in several animal models of autoimmune diseases19,20. A subset of 
Tregs known as natural Tregs (nTregs) leave the thymus as fully 
differentiated cells, whereas another subset, inducible Tregs 
(iTregs), can be induced from naïve Th0 cells21. Both subsets 
are characterized by the expression of the transcription factor 
forkhead box protein 3 (FOXP3) and mediate their action in 
part via the secretion of interleukin-10 (IL-10) and transforming 
growth factor beta (TGF-β)22 and in part by mechanisms involving 
cell-to-cell contact23. Loss of peripheral self-tolerance is con-
sidered to be the result of an overweight of Th17 cell response 
as compared with induced regulatory Th10 cell response18. 
FOXP3 is involved in the peripheral self-tolerance processes by 
promoting the development of Tregs while inhibiting the differ-
entiation of Th17 cells21. Mutations of the Foxp3 gene can cause 
the immune dysregulation, polyendocrinopathy, enteropathy, 
X-linked (IPEX) syndrome, an early-onset, life-threatening 
autoimmunity characterized by substantial polyautoimmunity 
and often death within two years of birth24. Under less severe 
circumstances, overexpression of FOXP3Δ2, a splice variant of 
FOXP3 lacking exon 225, may be associated with a shift toward 
a Th17 response, thereby increasing autoantibody production, 
as shown in a recent study of patients with HT26. Accordingly, a 
skewed balance between Th17 cells and Tregs18,21,26 as well as dys-
functional Tregs19 have been demonstrated in autoimmune disease 
in humans. A shift between Th10 and Th17 cells may occur according 
to the cytokine milieu in the microenvironment18,27. Recently, regu-
latory B cells (Bregs) have received much attention as inhibitors 
of inflammatory and autoimmune responses by the production of 
regulatory cytokines (primarily IL-10)18. Another factor that may 
contribute to the development of autoimmune disease is therefore 
a cytokine expression dominated by effector B cells rather than by 
Bregs. Thus, both Tregs and Bregs contribute to the maintenance of 
peripheral tolerance (Figure 1).
Development of autoimmune disease
The transition from natural to clinically manifesting autoimmu-
nity relies on an interplay between genetic predispositions and 
environmental events, as depicted in Weetman’s “Swiss cheese 
model” on AITD (Figure 2)28. Most autoimmune diseases are asso-
ciated with specific variants of the human leukocyte antigen (HLA) 
genes. Several other genetic polymorphisms have been associated 
with autoimmune diseases, particularly some located at the genes 
encoding cytotoxic T lymphocyte-associated 4 (CTLA-4) and the 
protein tyrosine phosphatase, non-receptor type 22 (PTPN22)29. 
Each of these loci encodes molecules involved in the regulation 
of T cells. In particular, two rare syndromes illustrate the impor-
tance of T cells in maintaining self-tolerance: the first, autoimmune 
polyglandular syndrome type I (APS 1, also called APECED), 
is caused by defects in the autoimmune regulator (AIRE) gene 
that mediates the induction of T-cell self-tolerance in the thy-
mus30. In patients with APS 1, multiple endocrine glands are dys-
functional. The second, FOXP3 deficiency, is associated with the 
IPEX syndrome, as mentioned above. Whereas APS 1 and IPEX 
syndrome are caused by mutation of a single gene, most cases of 
autoimmunity are likely the result of a broad range of genetic 
predispositions and environmental factors resulting in an 
imbalance of the peripheral self-tolerance mechanisms sustained 
by Tregs and Bregs (Figure 1)18. Thus, genetic polymorphisms in 
self-antigens, cytokines, estrogen receptors, and adhesion mol-
ecules have also been linked to the development of autoimmune 
disease28,31–36, as have genes coding for apoptotic processes37.
Figure 2. Etiology of thyroid autoimmunity. The development of autoimmune thyroid disease is a result of multiple events—a “Swiss cheese 
model”. Figure reproduced with kind permission from Weetman28. HLA, human leukocyte antigen. 
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In addition to genetic variation, both post-transcriptional and 
post-translational events may contribute to the development of 
autoimmunity. Thus, translation of mRNA into protein may be 
regulated by binding of RNA-binding protein and microRNAs, 
and alternative splicing of mRNA may influence the functionality 
of encoded proteins38. As mentioned above, certain splice variants 
of FOXP3 mRNA have been associated with autoimmune disease, 
including HT26,39,40. An example of post-translational modification 
that enhances the immunogenicity of self-proteins is the conver-
sion of arginine residues into citrulline residues, which has a major 
impact on autoantibody formation in rheumatoid arthritis41.
Several environmental factors may trigger autoimmune disease in 
genetically predisposed individuals, including bacterial and viral 
infections, cigarette smoking, maternal-fetal microchimerism42,43, 
and exposure to chemical compounds (flame retardants and 
phthalates)44, to mention but a few. Finally, being female predis-
poses to many autoimmune diseases, which may relate to hormonal 
factors and to X-chromosome inactivation patterns45,46.
Autoimmune thyroid disease
AITD is increasingly viewed as a continuum not only including 
distinct disease entities—that is, HT, GD, subacute thyroiditis, pri-
mary myxedema, and Graves’ orbitopathy (GO)—but covering a 
spectrum of diseases affecting the thyroid gland. However, in most 
thyroid research and in clinical practice, the two main entities of 
AITD remain as GD and HT with typically opposing main clini-
cal manifestations: hyperthyroidism and hypothyroidism, respec-
tively. In line with a more flexible view of AITD, both HT and 
GD are heterogeneous and can cause both hyperthyroidism and 
hypothyroidism47, even alternating between one form and the other48. 
GD and HT are among the most common autoimmune diseases 
in Western countries49. The pathogenesis is complex with a wide 
range of predisposing environmental, endogenous, and genetic 
factors, as described above and specified in relation to AITD in 
Box 145,46,50–52.
HT is characterized by a direct T-cell attack on the thyroid gland, 
leading to thyroiditis and subsequent exposure of thyroid antigens 
(thyroid peroxidase and thyroglobulin) against which antibodies are 
then produced. Thyroglobulin antibodies (TgAbs) and thyroid per-
oxidase antibodies (TPOAbs) are commonly associated with HT 
with a destructive pattern and are considered diagnostic for this dis-
ease. In any iodine-sufficient population, however, the prevalence 
of TPOAbs and TgAbs is much higher than that of clinical disease, 
amounting to approximately 15–25%, with the highest prevalence 
in females and increasing with age53. GD is also primarily caused 
by a T-cell abnormality, but the hyperthyroidism associated with 
the disease is caused by the production of the pathognomonic thy-
rotropin receptor autoantibodies (TRAbs). The stimulating effect of 
TRAbs on thyrocytes probably has an influence on the formation 
of TgAbs and TPOAbs as well54. GD (and less commonly HT) can 
be complicated by GO, an autoimmune reaction in the orbita caus-
ing fibroadipose tissue and extraocular muscles to increase in size 
with a risk of permanent damage to the optic nerve. Shared antigens 
between the thyroid and orbita have been suspected to be the tar-
get of the autoimmune response, and TRAbs are likely to play a 
part in the pathogenesis. A general inflammatory cytokine profile 
(mainly Th1-driven) and autoimmune reactions toward the insu-
lin-like growth factor 1 receptor (IGF-1R) have been demonstrated 
as well55.
Polyautoimmune disease
Occasionally, patients suffer from more than one well- 
defined autoimmune disease. In the 1950s, it was recognized that 
certain “shared threads” characterized autoimmune diseases56,57, 
a notion which has since been the subject of much debate and 
research. Many terms have been suggested for such conditions: 
polyautoimmunity2,58, autoimmune diathesis57, autoimmune 
tautology59, or, in the case of three or more coexisting autoimmune 
diseases, multiple autoimmune syndromes60. Lack of a common 
terminology challenges any comprehensive literature search and 
review. In the following, the term “polyautoimmunity” is used to 
describe the coexistence of two or more autoimmune diseases in 
the same patient.
Several endocrine syndromes including more than one autoim-
mune disease have been described (a sample of them is illustrated 
in Table 161–64). In polyglandular autoimmune syndrome type 2, 
Addison’s disease occurs with AITD or type 1 diabetes (as well 
as with other autoimmune presentations)61. Such syndromes or 
classified clusters are rare in contrast to the presence of multiple 
autoantibodies (independent of clinical diagnoses) in patients with 
autoimmune disease. AITD, being the most common, is prevalent 
in most polyautoimmune syndromes and cases. The following 
sections describe the clinical findings related to thyroid autoimmu-
nity in association with other autoimmunity.
Box 1. Risk factors for autoimmune thyroid disease
Environmental
▪   Iodine consumption
▪   Smoking (possibly protective)
▪   Radiation
▪   Drugs (including biologic agents)
▪   Alcohol consumption (protective)
▪   Pollutants
▪   Selenium? Vitamin D?
▪   Infections (Yersinia enterocolitica)?
▪   Improved hygiene?
Endogenous
▪   Female sex
▪   Parity
▪   Aging
▪   Stress hormones
▪   Fetal microchimerism
Genetic
▪   Chromosome abnormalities
▪   Human leukocyte antigen types?
▪   Single-nucleotide polymorphisms?
Page 5 of 12
F1000Research 2017, 6(F1000 Faculty Rev):1776 Last updated: 28 SEP 2017
Table 1. Polyautoimmune endocrine syndromes including thyroid disease.
Clusters Proposed pathogenic mechanism
Autoimmune polyglandular syndromes61
     Type I (autoimmune polyglandular syndrome type I  
or Whitaker syndrome): mucosal and cutaneous 
Candida infections, Addison’s disease, hyposplenism, 
hypoparathyroidism, and multiple autoimmune 
presentations (that is, hypothyroidism, hypogonadism, 
vitiligo, alopecia, pernicious anemia, and chronic 
autoimmune hepatitis)
Mutation of autoimmune regulator (AIRE) 
gene involved in central tolerance 
development. Phenotype possibly affected 
by human leukocyte antigen (HLA) 
subtypes62.
     Type II (Schmidt’s syndrome): Addison’s disease and 
hypothyroidism or type 1A diabetes as well as pernicious 
anemia, primary hypogonadism, vitiligo, celiac disease, 
and myasthenia gravis (by some further classified in 
types III and IV according to specific entities above)
Polygenetic with increased risk of disease 
linked to specific HLA-DR and HLA-DQ 
genotypes63
Immune dysregulation, polyendocrinopathy, enteropathy, 
X-linked (IPEX) syndrome24 
     Immune dysfunction, enteropathy, dermatitis, autoimmune 
endocrinopathies (often type 1 diabetes and autoimmune 
thyroid disease), autoimmune skin diseases (that is, 
bullous pemphigoid), and multiple organ involvement
Mutation of FOXP3 gene on the X 
chromosome
Multiple autoimmune syndromes60
    Type I: myasthenia gravis, thymoma, polymyositis, and 
    giant cell myocarditis
     Type II: Sjögren’s syndrome, rheumatoid arthritis, primary 
biliary cirrhosis, scleroderma, and autoimmune thyroid 
disorders
     Type III: autoimmune thyroid disease, myasthenia and/or 
thymoma, Sjögren’s syndrome, pernicious anemia, 
idiopathic thrombocytopenic purpura, Addison’s disease, 
insulin-dependent diabetes, vitiligo, autoimmune 
hemolytic anemia, and systemic lupus erythematosus
Genetic predisposition, with phenotype 
HLA B8 and/or DR3 or DR5 seeming to be 
an important factor
Thyrogastric cluster64 
     Autoimmune thyroiditis, chronic gastritis/pernicious 
anemia, and autoimmune adrenalitis (Addison’s)
Polygenetic
Lupus-associated cluster64 
     Autoimmune hemolytic anemia, immune 
thrombocytopenia, systemic lupus erythematosus, 
rheumatoid arthritis, autoimmune hepatitis, and Sjögren’s 
syndrome
Polygenetic
Trisomy 21 and Turner syndrome64 
    Chronic thyroiditis, type 1A diabetes, and others
Chromosomal abnormalities
Kearns-Sayre syndrome64 
     External ophthalmoplegia, retinal degeneration, diabetes, 
thyroiditis, and hypoparathyroidism
Mitochondrial myopathy
Thyroid autoimmunity in association with 
polyautoimmunity
Thyroid autoimmunity in other autoimmune disease
It is beyond the scope of this review to cover the numerous case 
reports describing polyautoimmunity. Instead, the present review 
will focus on clinical studies on polyautoimmunity involving 
AITD. In many studies, no distinction has been made between the 
various clinical phenotypes of AITD, and TgAbs, TPOAbs, and 
even TRAbs are often just referred to as “thyroid autoantibodies”, 
making reported percentages indicative only.
In a Colombian study2, patterns of clustering were investigated 
among 1,083 patients. The patients had systemic lupus erythemato-
sus, rheumatoid arthritis, systemic sclerosis, or multiple sclerosis. 
AITD was the most prevalent disease, coexisting with systemic 
sclerosis in 23% of cases, rheumatoid arthritis in 21% of cases, 
systemic lupus erythematosus in 18% of cases, and multiple scle-
rosis in 9%2. No control group was provided to substantiate the 
findings. Among 479 patients with primary Sjögren’s syndrome, 
Zeher et al. found 21% with AITD65. Another study from the same 
group showed that HT was significantly more prevalent than GD 
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in patients with mixed connective tissue disease, rheumatoid arthritis, 
and Sjögren’s syndrome and that both AITDs were much more 
prevalent in such patients than in the background population66. 
A total of 8.2% of investigated patients with the investigated 
systemic autoimmune diseases had AITD based on clinical 
evaluation, imaging, and fine needle aspiration cytology66.
A few studies of autoantibody prevalence have included healthy 
controls. Nakamura et al.67 found significant increases in TgAb and 
TPOAb positivity in all investigated autoimmune diseases com-
pared with healthy controls: up to 50% in type 1 diabetes, 55% in 
autoimmune liver disease, 26% in myasthenia gravis, and 34% in 
connective tissue diseases67. Only patients with type 1 diabetes had 
TRAbs more often than healthy controls (20% versus 0%, P <0.01). 
Interestingly, Liao et al.68 found no significant difference in thyroid 
autoantibody positivity between 1,290 patients with rheumatoid 
arthritis and 1,236 controls without rheumatic disease (TPOAbs 
15.6% versus 15.9%, TgAbs 1.1% versus 0.7%, P >0.05)68. We 
have previously found TPOAbs in 5% of patients with rheumatoid 
arthritis, 19% with type 1 diabetes mellitus, 11% with Sjögren’s 
syndrome, 56% with pernicious anemia, and 22% with primary bil-
iary cirrhosis compared with 98% with HT and 7% in healthy con-
trols, which is in keeping with the above-mentioned increased risk 
of autoimmune disease and not only positivity for autoantibody69.
Non-thyroid autoantibodies and other autoimmune disease 
in autoimmune thyroid disease
Few studies have investigated the prevalence of non-thyroid 
autoantibodies or other autoimmune diseases in patients with 
AITD. In a recently published prospective study, 3,069 patients 
with chronic AITD were compared with 1,023 patients with non-
toxic nodular goiter and 1,023 healthy controls70. Diagnosis of 
autoimmune disease was confirmed by a specialist according to 
scientific societies’ criteria. Several of the concurrent autoimmune 
diseases were significantly more prevalent in patients with AITD 
than in the healthy controls. However, only three concurrent dis-
eases had a prevalence of more than 2% in the AITD group: chronic 
autoimmune gastritis, vitiligo, and rheumatoid arthritis. Among 
observed clusters of disease, AITD together with chronic autoim-
mune gastritis and vitiligo formed a cluster with a significantly 
increased prevalence in the group of patients with AITD (12 patients 
versus 0 in other groups, P = 0.02)70.
In a Japanese population of patients with AITD, anti-glutamic acid 
decarboxylase antibodies were the most prevalent non-thyroid 
autoantibodies, being present in 6.4% of GD and in 4.6% of patients 
with HT67, thus confirming historical links between insulin antibod-
ies and thyroid autoimmunity71. In a study of more than 3,000 UK 
patients with AITD, there was a significantly increased relative 
risk of any other autoimmune disease screened for compared with 
the background population72. Thus, 14.3% of the 495 patients with 
HT and 9.7% with GD had at least one other autoimmune disease, 
mainly type 1 diabetes, rheumatoid arthritis, and pernicious ane-
mia. Wiebolt et al. investigated 359 patients with HT and 523 with 
GD and found differing patterns of autoantibody clustering in the 
two diseases73. Thus, adrenal autoimmunity combined with beta-
cell or gastric autoimmunity was more common in patients with HT 
compared with patients with GD73.
Epidemiological studies
Lack of power in clinical studies is made up for in epidemiologic 
studies. Eaton et al. included data from more than 5 million Danes 
from hospital registries to investigate the prevalence of 31 specified 
autoimmune diseases (based on the International Classification of 
Diseases 10th Revision (ICD10) classification system)74,75. Although 
data were limited to that of specialized care, the estimated lifetime 
prevalence of any autoimmune disease was 5.3%, and AITD most 
often coexisted with adrenal disease (odds ratio (OR) 12.9), alo-
pecia areata (OR 11.4), vitiligo (OR 7.9), and pernicious anemia 
(OR 5.6)75. However, compared with connective tissue diseases in 
particular, AITD showed limited overlap with other autoimmune 
diseases. As many patients with autoimmune disease are handled 
in general practice, a British study used the United Kingdom 
General Practice Research Database to study the intra-individual 
risk of polyautoimmunity76. Along with large numbers of patients 
with insulin-dependent diabetes mellitus, rheumatoid arthritis, and 
multiple sclerosis, 26,198 patients with AITD were included. Patients 
with either AITD or rheumatoid arthritis were at risk of develop-
ing the other disease (sex-specific standardized incidence rate of 
130.4–162.0)76. The risk of patients with type 1 diabetes having 
AITD was increased significantly in comparison with the back-
ground population having AITD; with a prevalence six times higher 
in males and a prevalence four times higher in females. This is in 
keeping with at least one previous cohort study, where patients with 
two autoimmune diseases, and thus probably stronger influence 
of genetic than environmental or other inherent factors, seemed 
to show a diminished or even abolished female preponderance of 
autoimmune diseases that is otherwise observed in the gen-
eral population77. Thus, the a priori likelihood of contract-
ing a second autoimmune disease is higher in males than in 
females with one autoimmune disease, which should be taken 
into account when managing male patients with AITD. Despite 
many inherent limitations, epidemiological studies provide 
further evidence of an increased risk of polyautoimmunity in 
patients with AITD. Without proving causality, the associa-
tion between AITD and other autoimmune diseases seems well 
substantiated and with no strict distinction between organ-specific 
and non-organ-specific autoimmune disease.
Clinical consequences of polyautoimmunity in 
thyroid autoimmunity
Clinical impact of (poly)autoimmunity
The chronic nature of autoimmune disease implies high socioeco-
nomic costs as well as a profound impact on the patient’s health 
and well-being78. The occurrence of polyautoimmunity rather 
than an isolated autoimmune disease may greatly affect progno-
sis. In a Dutch study, TPOAb positivity in patients with rheuma-
toid arthritis was predictive of disease activity—measured by the 
Disease Activity Score using 28 joint counts (DAS28)—and of 
increased carotid intima-media thickness at a 2-year follow-up79. 
The latter finding may indicate an increased risk of cardiovascular 
disease in patients with polyautoimmunity in accordance with the 
well-established association between increased inflammation and 
risk of cardiovascular disease80,81. In studies of reproductive fail-
ure, especially autoantibodies involved in the anti-phospholipid 
syndrome (that is, anti-cardiolipin antibodies)82 but also thyroid 
autoantibodies83,84 have been associated with worsened pregnancy 
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outcomes. In a study by Iijima et al.85, several autoantibodies were 
analyzed, and women with autoantibodies against one or more self-
antigens had a significantly increased risk of miscarriage. However, 
only 5% of all women (25.8% of autoantibody-positive women) had 
multiple autoantibodies85. In women with recurrent pregnancy loss, 
a thorough examination of possible polyautoimmune etiology is 
therefore warranted, and immunotherapy appears to be beneficial86.
Few studies indicate an impact of an underlying immunological 
tolerance breach rather than thyroid dysfunction on the symptoma-
tology involved in AITD. Abnormal brain perfusion in patients with 
euthyroid HT compared with controls has led to a hypothesis of 
an autoimmune component in decreased vascularization, possibly 
causing psychiatric symptoms in patients with AITD87,88. Also, a 
study of patient-reported outcomes (PROs) in Danish patients 
with AITD found a significant continuous reduction of outcomes, 
including physical functioning despite euthyroidism89. A subse-
quent study found reduced PROs in patients with GD compared 
with patients with toxic nodular goiter but failed to show an 
association with thyroid antibody levels90. Conversely, in studies of 
patients with systemic sclerosis and myasthenia gravis, those with 
coexistent AITD were less affected by their disease than patients 
without thyroid autoimmunity91,92. Thus, quantitative increments of 
autoimmune diagnoses are not always associated with a worsened 
prognosis.
The possible negative attribution of underlying autoimmunity (for 
example, GD) rather than thyroid function impairment (for exam-
ple, multinodular goiter) needs further investigation. The presence 
of a more general but undiagnosed polyautoimmunity could explain 
the poorer outcomes of treatment. This has in recent years been 
acknowledged by endocrinologists and is now introduced in clini-
cal guidelines (for example, for the treatment of hypothyroidism)93. 
Before combination therapy with thyroxine and triiodothyronine 
is considered, a search for other autoimmune diseases in a patient 
with AITD and poor PROs is now mandatory93. Thus, it has become 
relevant to both the clinician and the patient with AITD to be aware 
of the possibility of polyautoimmunity, not only as an explanatory 
model of prolonged symptoms but also with respect to a possible 
altered prognosis of disease and treatment outcome.
The role of immunomodulatory biologic drugs
The prevalence of thyroid and other autoimmunity will likely be 
affected by the increasing administration of biologic agents in 
cancer treatment and internal medicine, developed to target specific 
parts of the immune system. In multiple sclerosis patients treated 
with the T cell–depleting anti-CD52 monoclonal antibody alemtu-
zumab, one third of patients developed GD between 6 and 31 weeks 
after treatment94. This was likely due to loss of T cell–mediated 
immunoregulation. Also, in patients with chronic hepatitis treated 
with interferon-alpha, up to 40% developed thyroid autoantibodies 
and 15% developed clinical AITD95,96. Stefan et al. found a direct 
impact of interferon-alpha on the activity of a thyroglobulin promo-
tor region with a specific single-nucleotide polymorphism involved 
in AITD97. Finally, biologic drugs stimulating the patient’s own 
immune response against cancer cells have proven efficient in 
fighting cancers but may induce various autoimmune diseases. 
Among such drugs are the checkpoint inhibitors ipilimumab 
(a monoclonal antibody targeting the CTLA-4 receptor) and 
nivolumab and pembrolizumab (blocking “programmed cell 
death 1” proteins on T cells, thus promoting anti-tumor activity). 
Autoimmune hypophysitis is seen in 4% of patients treated with 
ipilimumab and in 1% of patients treated with nivolumab or pem-
brolizumab. Combined treatment with ipilimumab and nivolumab 
increases the hypophysitis rate to 8%98. In these patients with 
autoimmune hypophysitis, secondary adrenal insufficiency 
develops in up to 100%, hypogonadotropic hypogonadism in 
up to 85%, and central hypothyroidism in up to 100%98. More 
rarely, autoimmune primary thyroid affection or adrenal insuf-
ficiency occurs99. Thus, the use of such drugs should entail a 
standardized monitoring program to check for endocrinopathies 
(i.e. life-threatening adrenal insufficiency) and thorough patient 
information including which symptoms to react upon.
On the other hand, biologic agents may offer new options for 
treating (poly)autoimmune diseases, including otherwise treat-
ment-resistant AITD. Treatment of rheumatic arthritis patients 
with biologic agents seems to be safe and to possibly have a posi-
tive effect on concurrent AITD100. In a small study, the treatment 
of 138 patients with rheumatoid arthritis with the tumor necrosis 
factor-alpha inhibitor adalimumab led to concurrent improve-
ment of hypothyroidism as well as a reduction in TPOAb levels101. 
Incorporation of rituximab, a B cell–depleting agent, has shown 
promising results in patients with GO102–104 in addition to amel-
iorating numerous other autoimmune diseases, such as rheuma-
toid arthritis103,105, multiple sclerosis106, and type 1 diabetes107. In 
a recent study, inhibition of the IGF-1R by use of teprotumumab, 
an antibody targeting the IGF-1R, also significantly improved 
outcome in 88 patients with GO108. The field of drugs targeting 
immune-mediated diseases is quickly evolving, and numerous 
drugs have been developed and are undergoing clinical trials109. 
Although the mechanisms triggering loss of self-tolerance are still 
unclear, the increasing knowledge about B-cell and T-cell subsets 
and different cytokine milieus provides interesting perspectives 
for refined treatment options in (poly)autoimmune diseases 
including treatment-resistant AITD. For a summary of learning 
points, see Box 2.
Conclusions
As illustrated above, AITD is often represented in patients with 
polyautoimmunity, and patients with AITD have an increased risk 
Box 2. Learning points
•     Polyautoimmunity in patients with autoimmune thyroid 
disease is common but not part of routine screening.
•     Polyautoimmunity may increase morbidity due to 
inflammation.
•     Patients with continuous complaints despite euthyroidism 
may benefit from wider immunological assessment.
•     Interdisciplinary assessment is beneficial for 
polyautoimmune patients.
•     Immunomodulatory biologic drugs may be a future 
treatment option in thyroid autoimmune patients with 
multiple associated autoantibodies.
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of developing other autoimmune diseases. In AITD patients with 
remaining complaints despite euthyroidism or patients presenting 
with new symptoms, polyautoimmunity should come to mind. 
Furthermore, the concept of polyautoimmunity may call for 
a rethinking of treatment strategies in patients with AITD. 
Current treatment of AITD has focused on securing thyroid 
hormone homeostasis, but in cases with polyautoimmunity more 
attention should be drawn to the identification and treatment 
of the underlying immune dysregulation and inflammation. In 
years to come, immunomodulatory biologic drugs may serve this 
purpose.
Author contributions
SB was in charge of the manuscript preparation. All authors con-
tributed to the conception, discussion, critical review, and approval 
of the manuscript in accordance with the requirements of the 
International Committee of Medical Journal Editors. All authors 
were involved in the revision of the draft manuscript and have 
agreed to the final content.
Competing interests
The authors declare that they have no competing interests.
Grant information
SB is kindly supported by grants from the Copenhagen University 
Hospital (Rigshospitalet) and the Musikforlæggerne Agnes and 
Knut Mørk Foundation. UF-R is supported by a grant from the 
Novo Nordisk Foundation. 
The funders had no role in study design, data collection and 
analysis, decision to publish, or preparation of the manuscript.
References F1000 recommended
1. Weetman A, DeGroot LJ: Autoimmunity to the Thyroid Gland. In: De Groot LJ, 
Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, et al., editors. 
Endotext. South Dartmouth (MA); 2000.  
PubMed Abstract 
2. Rojas-Villarraga A, Amaya-Amaya J, Rodriguez-Rodriguez A, et al.: Introducing 
polyautoimmunity: secondary autoimmune diseases no longer exist. 
Autoimmune Dis. 2012; 2012: 254319.  
PubMed Abstract | Publisher Full Text | Free Full Text 
3. Ehrlich P: Verh Ges Dtsch Naturforsch. 1902; 1: 250–275. 
4. Welch WH: The Huxley Lecture on Recent Studies of Immunity, with Special 
Reference to their Bearing on Pathology: Delivered at the Opening of the 
Winter Session of Charing Cross Hospital Medical School on October 1st, 
1902. Br Med J. 1902; 2(2180): 1105–14.  
PubMed Abstract | Free Full Text 
5. Metalnikoff S: Ann Inst Pasteur. 1900; 14: 577–589. 
6. Avrameas S, Selmi C: Natural autoantibodies in the physiology and 
pathophysiology of the immune system. J Autoimmun. 2013; 41: 46–9.  
PubMed Abstract | Publisher Full Text 
7. Nakamura M, Burastero SE, Ueki Y, et al.: Probing the normal and autoimmune 
B cell repertoire with Epstein-Barr virus. Frequency of B cells producing 
monoreactive high affinity autoantibodies in patients with Hashimoto’s 
disease and systemic lupus erythematosus. J Immunol. 1988; 141(12): 4165–72. 
PubMed Abstract 
8. Berneman A, Guilbert B, Eschrich S, et al.: IgG auto- and polyreactivities of 
normal human sera. Mol Immunol. 1993; 30(16): 1499–510.  
PubMed Abstract 
9. Nielsen CH, Bendtzen K: Immunoregulation by naturally occurring and disease-
associated autoantibodies: binding to cytokines and their role in regulation of 
T-cell responses. Adv Exp Med Biol. 2012; 750: 116–32.  
PubMed Abstract | Publisher Full Text 
10. Nielsen CH, Brix TH, Gardas A, et al.: Epitope recognition patterns of 
thyroid peroxidase autoantibodies in healthy individuals and patients with 
Hashimoto’s thyroiditis*. Clin Endocrinol (Oxf). 2008; 69(4): 664–8.  
PubMed Abstract | Publisher Full Text 
11. Hayakawa K, Asano M, Shinton SA, et al.: Positive selection of natural 
autoreactive B cells. Science. 1999; 285(5424): 113–6.  
PubMed Abstract | Publisher Full Text 
12. Nossal GJ: Negative selection of lymphocytes. Cell. 1994; 76(2): 229–39. 
PubMed Abstract | Publisher Full Text 
13. Webb S, Morris C, Sprent J: Extrathymic tolerance of mature T cells: clonal 
elimination as a consequence of immunity. Cell. 1990; 63(6): 1249–56.  
PubMed Abstract | Publisher Full Text 
14. Lutz HU, Binder CJ, Kaveri S: Naturally occurring auto-antibodies in 
homeostasis and disease. Trends Immunol. 2009; 30(1): 43–51.  
PubMed Abstract | Publisher Full Text 
15. Hurez V, Dietrich G, Kaveri SV, et al.: Polyreactivity is a property of natural and 
disease-associated human autoantibodies. Scand J Immunol. 1993; 38(2): 190–6. 
PubMed Abstract | Publisher Full Text 
16. Rapoport B, McLachlan SM: Graves’ hyperthyroidism is antibody-mediated but 
is predominantly a Th1-type cytokine disease. J Clin Endocrinol Metab. 2014; 
99(11): 4060–1.  
PubMed Abstract | Publisher Full Text | Free Full Text 
17. Figueroa-Vega N, Alfonso-Pérez M, Benedicto I, et al.: Increased circulating  
pro-inflammatory cytokines and Th17 lymphocytes in Hashimoto’s thyroiditis. 
J Clin Endocrinol Metab. 2010; 95(2): 953–62.  
PubMed Abstract | Publisher Full Text 
18.  Papp G, Boros P, Nakken B, et al.: Regulatory immune cells and functions 
in autoimmunity and transplantation immunology. Autoimmun Rev. 2017; 16(5): 
435–44.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
19. Ramos-Leví AM, Marazuela M: Pathogenesis of thyroid autoimmune disease: 
the role of cellular mechanisms. Endocrinol Nutr. 2016; 63(8): 421–9.  
PubMed Abstract | Publisher Full Text 
20. Morris GP, Brown NK, Kong YM: Naturally-existing CD4(+)CD25(+)Foxp3(+) 
regulatory T cells are required for tolerance to experimental autoimmune 
thyroiditis induced by either exogenous or endogenous autoantigen.  
J Autoimmun. 2009; 33(1): 68–76.  
PubMed Abstract | Publisher Full Text | Free Full Text 
21.  González-Amaro R, Marazuela M: T regulatory (Treg) and T helper 17 (Th17) 
lymphocytes in thyroid autoimmunity. Endocrine. 2016; 52(1): 30–8.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
22. Roncarolo MG, Gregori S, Battaglia M, et al.: Interleukin-10-secreting type 1 
regulatory T cells in rodents and humans. Immunol Rev. 2006; 212: 28–50. 
PubMed Abstract | Publisher Full Text 
23. von Boehmer H: Mechanisms of suppression by suppressor T cells. Nat 
Immunol. 2005; 6(4): 338–44.  
PubMed Abstract | Publisher Full Text 
24. Bennett CL, Christie J, Ramsdell F, et al.: The immune dysregulation, 
polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by 
mutations of FOXP3. Nat Genet. 2001; 27(1): 20–1.  
PubMed Abstract | Publisher Full Text 
25. Allan SE, Passerini L, Bacchetta R, et al.: The role of 2 FOXP3 isoforms in the 
generation of human CD4+ Tregs. J Clin Invest. 2005; 115(11): 3276–84.  
PubMed Abstract | Publisher Full Text | Free Full Text 
26. Kristensen B, Hegedüs L, Madsen HO, et al.: Altered balance between self-
reactive T helper (Th)17 cells and Th10 cells and between full-length forkhead 
box protein 3 (FoxP3) and FoxP3 splice variants in Hashimoto’s thyroiditis. 
Clin Exp Immunol. 2015; 180(1): 58–69.  
PubMed Abstract | Publisher Full Text | Free Full Text 
27. Yanaba K, Bouaziz J, Haas KM, et al.: A regulatory B cell subset with a unique 
CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. 
Immunity. 2008; 28(5): 639–50.  
PubMed Abstract | Publisher Full Text 
28.  Weetman AP: The immunopathogenesis of chronic autoimmune thyroiditis 
one century after hashimoto. Eur Thyroid J. 2013; 1(4): 243–50.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
Page 9 of 12
F1000Research 2017, 6(F1000 Faculty Rev):1776 Last updated: 28 SEP 2017
29. Brand O, Gough S, Heward J: HLA, CTLA-4 and PTPN22: the shared genetic 
master-key to autoimmunity? Expert Rev Mol Med. 2005; 7(23): 1–15.  
PubMed Abstract | Publisher Full Text 
30. Mathis D, Benoist C: Aire. Annu Rev Immunol. 2009; 27: 287–312.  
PubMed Abstract | Publisher Full Text 
31. Caputo M, Rivolta CM, Mories T, et al.: Analysis of thyroglobulin gene 
polymorphisms in patients with autoimmune thyroiditis. Endocrine. 2010; 37(3): 
389–95.  
PubMed Abstract | Publisher Full Text 
32.  Zenewicz LA, Abraham C, Flavell RA, et al.: Unraveling the genetics of 
autoimmunity. Cell. 2010; 140(6): 791–7.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
33. Johar AS, Mastronardi C, Rojas-Villarraga A, et al.: Novel and rare functional 
genomic variants in multiple autoimmune syndrome and Sjögren’s syndrome. 
J Transl Med. 2015; 13: 173.  
PubMed Abstract | Publisher Full Text | Free Full Text 
34. Johar AS, Anaya JM, Andrews D, et al.: Candidate gene discovery in 
autoimmunity by using extreme phenotypes, next generation sequencing and 
whole exome capture. Autoimmun Rev. 2015; 14(3): 204–9.  
PubMed Abstract | Publisher Full Text 
35. Chu X, Pan CM, Zhao SX, et al.: A genome-wide association study identifies 
two new risk loci for Graves’ disease. Nat Genet. 2011; 43(9): 897–901.  
PubMed Abstract | Publisher Full Text 
36. Lee HS, Kang J, Yang S, et al.: Susceptibility influence of a PTPN22 haplotype 
with thyroid autoimmunity in Koreans. Diabetes Metab Res Rev. 2011; 27(8): 
878–82.  
PubMed Abstract | Publisher Full Text 
37.  Johar A, Sarmiento-Monroy JC, Rojas-Villarraga A, et al.: Definition of 
mutations in polyautoimmunity. J Autoimmun. 2016; 72: 65–72.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
38.  Chen JQ, Papp G, Szodoray P, et al.: The role of microRNAs in the 
pathogenesis of autoimmune diseases. Autoimmun Rev. 2016; 15(12): 1171–80.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
39. Link M, Salur L, Kisand K, et al.: Higher FoxP3 mRNA expression in peripheral 
blood mononuclear cells of GAD65 or IA-2 autoantibody-positive compared 
with autoantibody-negative persons. APMIS. 2008; 116(10): 896–902.  
PubMed Abstract | Publisher Full Text 
40. Ryder LR, Bartels EM, Woetmann A, et al.: FoxP3 mRNA splice forms in synovial 
CD4+ T cells in rheumatoid arthritis and psoriatic arthritis. APMIS. 2012; 
120(5): 387–96.  
PubMed Abstract | Publisher Full Text 
41.  Catrina AI, Svensson CI, Malmström V, et al.: Mechanisms leading from 
systemic autoimmunity to joint-specific disease in rheumatoid arthritis.  
Nat Rev Rheumatol. 2017; 13(2): 79–86.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
42. Lepez T, Vandewoestyne M, Deforce D: Fetal microchimeric cells in autoimmune 
thyroid diseases: harmful, beneficial or innocent for the thyroid gland? 
Chimerism. 2013; 4(4): 111–8.  
PubMed Abstract | Publisher Full Text | Free Full Text 
43.  Stevens AM: Maternal microchimerism in health and disease. Best Pract 
Res Clin Obstet Gynaecol. 2016; 31: 121–30.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
44. Mynster Kronborg T, Frohnert Hansen J, Nielsen CH, et al.: Effects of the 
Commercial Flame Retardant Mixture DE-71 on Cytokine Production by 
Human Immune Cells. PLoS One. 2016; 11(4): e0154621.  
PubMed Abstract | Publisher Full Text | Free Full Text 
45. Gleicher N, Barad DH: Gender as risk factor for autoimmune diseases.  
J Autoimmun. 2007; 28(1): 1–6.  
PubMed Abstract | Publisher Full Text 
46.  Brix TH, Hegedüs L: Twin studies as a model for exploring the aetiology of 
autoimmune thyroid disease. Clin Endocrinol (Oxf). 2012; 76(4): 457–64.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
47. Bech K, Bliddal H, Feldt-Rasmussen U, et al.: Heterogeneity of autoimmune 
thyroiditis. Allergy. 1984; 39(4): 239–47.  
PubMed Abstract | Publisher Full Text 
48. DeGroot LJ: Diagnosis and Treatment of Graves’ Disease. In: De Groot LJ, 
Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, et al., editors. 
Endotext. South Dartmouth (MA); 2000.  
PubMed Abstract 
49. Vanderpump MP: The epidemiology of thyroid disease. Br Med Bull. 2011; 99: 
39–51.  
PubMed Abstract | Publisher Full Text 
50.  Pedersen IB, Knudsen N, Carlé A, et al.: A cautious iodization programme 
bringing iodine intake to a low recommended level is associated with an 
increase in the prevalence of thyroid autoantibodies in the population. Clin 
Endocrinol (Oxf). 2011; 75(1): 120–6.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
51. Jørgensen KT, Pedersen BV, Nielsen NM, et al.: Childbirths and risk of female 
predominant and other autoimmune diseases in a population-based Danish 
cohort. J Autoimmun. 2012; 38(2–3): J81–7.  
PubMed Abstract | Publisher Full Text 
52. Hansen PS, Brix TH, Iachine I, et al.: The relative importance of genetic and 
environmental effects for the early stages of thyroid autoimmunity: a study of 
healthy Danish twins. Eur J Endocrinol. 2006; 154(1): 29–38.  
PubMed Abstract | Publisher Full Text 
53. Pedersen IB, Knudsen N, Jørgensen T, et al.: Thyroid peroxidase and 
thyroglobulin autoantibodies in a large survey of populations with mild and 
moderate iodine deficiency. Clin Endocrinol (Oxf). 2003; 58(1): 36–42.  
PubMed Abstract | Publisher Full Text 
54. Rasmussen AK, Feldt-Rasmussen U, Brandt M, et al.: Thyrotropin stimulates 
specifically the expression of the autoantibody binding domains of the 
thyroperoxidase molecule. Autoimmunity. 1999; 29(4): 323–31.  
PubMed Abstract | Publisher Full Text 
55.  Smith TJ, Hegedüs L: Graves’ Disease. N Engl J Med. 2016; 375: 1552–65. 
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
56. WITEBSKY E, ROSE NR, TERPLAN K, et al.: Chronic thyroiditis and 
autoimmunization. J Am Med Assoc. 1957; 164(13): 1439–47.  
PubMed Abstract | Publisher Full Text 
57. Rose NR: Autoimmune diseases: tracing the shared threads. Hosp Pract (1995). 
1997; 32(4): 147–54.  
PubMed Abstract | Publisher Full Text 
58. Sheehan NJ, Stanton-King K: Polyautoimmunity in a young woman. Br J 
Rheumatol. 1993; 32(3): 254–6.  
PubMed Abstract | Publisher Full Text 
59. Anaya JM, Castiblanco J, Rojas-Villarraga A, et al.: The multiple autoimmune 
syndromes. A clue for the autoimmune tautology. Clin Rev Allergy Immunol. 
2012; 43(3): 256–64.  
PubMed Abstract | Publisher Full Text 
60. Humbert P, Dupond JL: [Multiple autoimmune syndromes]. Ann Med Interne 
(Paris). 1988; 139(3): 159–68.  
PubMed Abstract 
61. Eisenbarth GS, Gottlieb PA: Autoimmune polyendocrine syndromes. N Engl J 
Med. 2004; 350(20): 2068–79.  
PubMed Abstract | Publisher Full Text 
62. Halonen M, Eskelin P, Myhre AG, et al.: AIRE mutations and human leukocyte 
antigen genotypes as determinants of the autoimmune polyendocrinopathy-
candidiasis-ectodermal dystrophy phenotype. J Clin Endocrinol Metab. 2002; 
87(6): 2568–74.  
PubMed Abstract | Publisher Full Text 
63. Myhre AG, Undlien DE, Løvås K, et al.: Autoimmune adrenocortical failure in 
Norway autoantibodies and human leukocyte antigen class II associations 
related to clinical features. J Clin Endocrinol Metab. 2002; 87(2): 618–23.  
PubMed Abstract | Publisher Full Text 
64. Mackay IR: Clustering and commonalities among autoimmune diseases.  
J Autoimmun. 2009; 33(3–4): 170–7.  
PubMed Abstract | Publisher Full Text 
65. Zeher M, Horvath IF, Szanto A, et al.: Autoimmune thyroid diseases in a large 
group of Hungarian patients with primary Sjögren’s syndrome. Thyroid. 2009; 
19(1): 39–45.  
PubMed Abstract | Publisher Full Text 
66. Biró E, Szekanecz Z, Czirják L, et al.: Association of systemic and thyroid 
autoimmune diseases. Clin Rheumatol. 2006; 25(2): 240–5.  
PubMed Abstract | Publisher Full Text 
67.  Nakamura H, Usa T, Motomura M, et al.: Prevalence of interrelated 
autoantibodies in thyroid diseases and autoimmune disorders. J Endocrinol 
Invest. 2008; 31(10): 861–5.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
68. Liao KP, Kurreeman F, Li G, et al.: Associations of autoantibodies, autoimmune 
risk alleles, and clinical diagnoses from the electronic medical records in 
rheumatoid arthritis cases and non-rheumatoid arthritis controls. Arthritis 
Rheum. 2013; 65(3): 571–81.  
PubMed Abstract | Publisher Full Text | Free Full Text 
69. Feldt-Rasmussen U, Høier-Madsen M, Bech K, et al.: Anti-thyroid peroxidase 
antibodies in thyroid disorders and non-thyroid autoimmune diseases. 
Autoimmunity. 1991; 9(3): 245–54.  
PubMed Abstract | Publisher Full Text 
70.  Fallahi P, Ferrari SM, Ruffilli I, et al.: The association of other autoimmune 
diseases in patients with autoimmune thyroiditis: Review of the literature 
and report of a large series of patients. Autoimmun Rev. 2016; 15(12): 1125–8. 
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
71. Di Mario U, Perfetti R, Anastasi E, et al.: Autoantibodies to insulin do appear 
in non-diabetic patients with autoimmune disorders: comparison with 
anti-immunoglobulin antibodies and other autoimmune phenomena. Acta 
Endocrinol (Copenh). 1990; 122(3): 303–8.  
PubMed Abstract | Publisher Full Text 
72.  Boelaert K, Newby PR, Simmonds MJ, et al.: Prevalence and relative risk of 
other autoimmune diseases in subjects with autoimmune thyroid disease.  
Am J Med. 2010; 123(2): 183.e1–9.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
73. Wiebolt J, Achterbergh R, den Boer A, et al.: Clustering of additional 
autoimmunity behaves differently in Hashimoto’s patients compared with 
Graves’ patients. Eur J Endocrinol. 2011; 164(5): 789–94.  
PubMed Abstract | Publisher Full Text 
Page 10 of 12
F1000Research 2017, 6(F1000 Faculty Rev):1776 Last updated: 28 SEP 2017
74. Eaton WW, Pedersen MG, Atladóttir HO, et al.: The prevalence of 30 ICD-10 
autoimmune diseases in Denmark. Immunol Res. 2010; 47(1–3): 228–31. 
PubMed Abstract | Publisher Full Text | Free Full Text 
75. Eaton WW, Rose NR, Kalaydjian A, et al.: Epidemiology of autoimmune diseases 
in Denmark. J Autoimmun. 2007; 29(1): 1–9.  
PubMed Abstract | Publisher Full Text | Free Full Text 
76. Somers EC, Thomas SL, Smeeth L, et al.: Are individuals with an autoimmune 
disease at higher risk of a second autoimmune disorder? Am J Epidemiol. 
2009; 169(6): 749–55.  
PubMed Abstract | Publisher Full Text 
77. Ottesen M, Feldt-Rasmussen U, Andersen J, et al.: Thyroid function and 
autoimmunity in pernicious anemia before and during cyanocobalamin 
treatment. J Endocrinol Invest. 1995; 18(2): 91–7.  
PubMed Abstract | Publisher Full Text 
78. Anaya JM: The diagnosis and clinical significance of polyautoimmunity. 
Autoimmun Rev. 2014; 13(4–5): 423–6.  
PubMed Abstract | Publisher Full Text 
79. Raterman HG, Voskuyl AE, Simsek S, et al.: Increased progression of carotid 
intima media thickness in thyroid peroxidase antibodies-positive rheumatoid 
arthritis patients. Eur J Endocrinol. 2013; 169(6): 751–7.  
PubMed Abstract | Publisher Full Text 
80. Willeit P, Thompson SG, Agewall S, et al.: Inflammatory markers and extent and 
progression of early atherosclerosis: Meta-analysis of individual-participant-
data from 20 prospective studies of the PROG-IMT collaboration. Eur J Prev 
Cardiol. 2016; 23(2): 194–205.  
PubMed Abstract | Publisher Full Text | Free Full Text 
81. Caforio AL, Wagner R, Gill JS, et al.: Organ-specific cardiac antibodies: serological 
markers for systemic hypertension in autoimmune polyendocrinopathy. Lancet. 
1991; 337(8750): 1111–5.  
PubMed Abstract | Publisher Full Text 
82. de Jesus GR, Agmon-Levin N, Andrade CA, et al.: 14th International Congress on 
Antiphospholipid Antibodies Task Force report on obstetric antiphospholipid 
syndrome. Autoimmun Rev. 2014; 13(8): 795–813.  
PubMed Abstract | Publisher Full Text 
83. Chen LM, Zhang Q, Si GX, et al.: Associations between thyroid autoantibody 
status and abnormal pregnancy outcomes in euthyroid women. Endocrine. 
2015; 48(3): 924–8.  
PubMed Abstract | Publisher Full Text 
84.  Thangaratinam S, Tan A, Knox E, et al.: Association between thyroid 
autoantibodies and miscarriage and preterm birth: meta-analysis of evidence. 
BMJ. 2011; 342: d2616.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
85.  Iijima T, Tada H, Hidaka Y, et al.: Effects of autoantibodies on the course of 
pregnancy and fetal growth. Obstet Gynecol. 1997; 90(3): 364–9.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
86.  Mekinian A, Cohen J, Alijotas-Reig J, et al.: Unexplained Recurrent 
Miscarriage and Recurrent Implantation Failure: Is There a Place for 
Immunomodulation? Am J Reprod Immunol. 2016; 76(1): 8–28.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
87. Piga M, Serra A, Deiana L, et al.: Brain perfusion abnormalities in patients with 
euthyroid autoimmune thyroiditis. Eur J Nucl Med Mol Imaging. 2004; 31(12): 
1639–44.  
PubMed Abstract | Publisher Full Text 
88. Montagna G, Imperiali M, Agazzi P, et al.: Hashimoto’s encephalopathy: A rare 
proteiform disorder. Autoimmun Rev. 2016; 15(5): 466–76.  
PubMed Abstract | Publisher Full Text 
89. Watt T, Hegedü sL, Bjorner JB, et al.: Is Thyroid Autoimmunity per se a 
Determinant of Quality of Life in Patients with Autoimmune Hypothyroidism? 
Eur Thyroid J. 2012; 1(3): 186–92.  
PubMed Abstract | Publisher Full Text | Free Full Text 
90. Bové KB, Watt T, Vogel A, et al.: Anxiety and depression are more prevalent in 
patients with graves’ disease than in patients with nodular goitre. Eur Thyroid J. 
2014; 3(3): 173–8.  
PubMed Abstract | Publisher Full Text | Free Full Text 
91. Avouac J, Airò P, Dieude P, et al.: Associated autoimmune diseases in systemic 
sclerosis define a subset of patients with milder disease: results from 2 large 
cohorts of European Caucasian patients. J Rheumatol. 2010; 37(3): 608–14. 
PubMed Abstract | Publisher Full Text 
92. Marinó M, Ricciardi R, Pinchera A, et al.: Mild clinical expression of myasthenia 
gravis associated with autoimmune thyroid diseases. J Clin Endocrinol Metab. 
1997; 82(2): 438–43.  
PubMed Abstract | Publisher Full Text 
93. Wiersinga WM, Duntas L, Fadeyev V, et al.: 2012 ETA Guidelines: The Use of  
L-T4 + L-T3 in the Treatment of Hypothyroidism. Eur Thyroid J. 2012; 1(2): 
55–71.  
PubMed Abstract | Publisher Full Text | Free Full Text 
94. Coles AJ, Wing M, Smith S, et al.: Pulsed monoclonal antibody treatment and 
autoimmune thyroid disease in multiple sclerosis. Lancet. 1999; 354(9191): 
1691–5.  
PubMed Abstract | Publisher Full Text 
95. Mandac JC, Chaudhry S, Sherman KE, et al.: The clinical and physiological 
spectrum of interferon-alpha induced thyroiditis: toward a new classification. 
Hepatology. 2006; 43(4): 661–72.  
PubMed Abstract | Publisher Full Text 
96. Antonelli A, Ferri C, Fallahi P: Hepatitis C: thyroid dysfunction in patients with 
hepatitis C on IFN-alpha therapy. Nat Rev Gastroenterol Hepatol. 2009; 6(11): 
633–5.  
PubMed Abstract | Publisher Full Text 
97. Stefan M, Jacobson EM, Huber AK, et al.: Novel variant of thyroglobulin 
promoter triggers thyroid autoimmunity through an epigenetic interferon 
alpha-modulated mechanism. J Biol Chem. 2011; 286(36): 31168–79.  
PubMed Abstract | Publisher Full Text | Free Full Text 
98.  Spain L, Diem S, Larkin J: Management of toxicities of immune checkpoint 
inhibitors. Cancer Treat Rev. 2016; 44: 51–60.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
99. Corsello SM, Barnabei A, Marchetti P, et al.: Endocrine side effects induced by 
immune checkpoint inhibitors. J Clin Endocrinol Metab. 2013; 98(4): 1361–75. 
PubMed Abstract | Publisher Full Text 
100. Bliddal S, Borresen SW, Feldt-Rasmussen U: Thyroid Autoimmunity and 
Function after Treatment with Biological Antirheumatic Agents in Rheumatoid 
Arthritis. Front Endocrinol (Lausanne). 2017; 8: 179.  
PubMed Abstract | Publisher Full Text | Free Full Text 
101. Raterman HG, Jamnitski A, Lems WF, et al.: Improvement of thyroid function in 
hypothyroid patients with rheumatoid arthritis after 6 months of adalimumab 
treatment: a pilot study. J Rheumatol. 2011; 38(2): 247–51.  
PubMed Abstract | Publisher Full Text 
102. El Fassi D, Nielsen CH, Hasselbalch HC, et al.: Treatment-resistant severe, active 
Graves’ ophthalmopathy successfully treated with B lymphocyte depletion. 
Thyroid. 2006; 16(7): 709–10.  
PubMed Abstract | Publisher Full Text 
103. Nielsen CH, El Fassi D, Hasselbalch HC, et al.: B-cell depletion with rituximab 
in the treatment of autoimmune diseases. Graves’ ophthalmopathy the latest 
addition to an expanding family. Expert Opin Biol Ther. 2007; 7(7): 1061–78. 
PubMed Abstract | Publisher Full Text 
104.  Salvi M, Vannucchi G, Currò N, et al.: Efficacy of B-cell targeted therapy 
with rituximab in patients with active moderate to severe Graves’ orbitopathy: 
a randomized controlled study. J Clin Endocrinol Metab. 2015; 100(2): 422–31. 
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
105. Buch MH, Smolen JS, Betteridge N, et al.: Updated consensus statement on the 
use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011; 
70(6): 909–20.  
PubMed Abstract | Publisher Full Text | Free Full Text 
106.  Hauser SL, Waubant E, Arnold DL, et al.: B-cell depletion with rituximab 
in relapsing-remitting multiple sclerosis. N Engl J Med. 2008; 358(7): 676–88. 
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
107.  Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, et al.: Rituximab,  
B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med. 
2009; 361(22): 2143–52.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
108.  Smith TJ, Kahaly GJ, Ezra DG, et al.: Teprotumumab for Thyroid-Associated 
Ophthalmopathy. N Engl J Med. 2017; 376(18): 1748–61.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
109.  Baker KF, Isaacs JD: Novel therapies for immune-mediated inflammatory 
diseases: What can we learn from their use in rheumatoid arthritis, 
spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease 
and ulcerative colitis? Ann Rheum Dis. 2017; pii: annrheumdis-2017-211555. 
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
Page 11 of 12
F1000Research 2017, 6(F1000 Faculty Rev):1776 Last updated: 28 SEP 2017
 Open Peer Review
  Current Referee Status:
Editorial Note on the Review Process
 are commissioned from members of the prestigious   and are edited as aF1000 Faculty Reviews F1000 Faculty
service to readers. In order to make these reviews as comprehensive and accessible as possible, the referees
provide input before publication and only the final, revised version is published. The referees who approved the
final version are listed with their names and affiliations but without their reports on earlier versions (any comments
will already have been addressed in the published version).
The referees who approved this article are:
Version 1
 Department of Clinical and Experimental Medicine, University of Pisa, Via Savi 10,Alessandro Antonelli
Pisa, 56126, Italy
 No competing interests were disclosed.Competing Interests:
1
 Service of Endocrinology, Hospital Universitario de la Princesa, Instituto de InvestigacionMaria Marazuela
Princesa, Universidad Autónoma de Madrid, Madrid, Spain
 No competing interests were disclosed.Competing Interests:
1
Page 12 of 12
F1000Research 2017, 6(F1000 Faculty Rev):1776 Last updated: 28 SEP 2017
